, Volume 71, Issue 10, pp 1355–1365


First Global Approval
R&D Insight Profile

DOI: 10.2165/11595310-000000000-00000

Cite this article as:
Commander, H., Whiteside, G. & Perry, C. Drugs (2011) 71: 1355. doi:10.2165/11595310-000000000-00000


Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). Regulatory submissions for this indication have been filed in the EU and Canada, with clinical development in malignant MTC ongoing in several other countries. Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer. Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development. This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Helen Commander
    • 1
  • Glenn Whiteside
    • 1
  • Caroline Perry
    • 2
  1. 1.R&D InsightWolters Kluwer Pharma SolutionsMairangi Bay, North Shore 0754, AucklandNew Zealand
  2. 2.Adis, a Wolters Kluwer BusinessAucklandNew Zealand